Maurizio Pastorello

Real-World Progression-Free Survival and Healthcare Resource Utilization Associated with Daratumumab Use in Transplant-Ineligible Multiple Myeloma Patients in Italy

Valentina Perrone, Gregorio Barilà, Luca Franceschini, Giuseppe Mele et autres

Purpose: This study evaluated real-world clinical and economic outcomes associated with daratumumab-based regimens in patients with multiple myeloma (MM) ineligible for autologous stem cell transplantation (ASCT) in Italy. Differences in healthcare resource use according to daratumumab administration route (intravenous vs subcutaneous) were …

gb, it, us, mv (code pays fourni par la source)

Characteristics, therapeutic pathway and the economic burden of patients with drug‐resistant epilepsy: A real‐world analysis following the introduction of cenobamate in Italy

Valentina Perrone, Chiara Veronesi, Maria Cappuccilli, Margherita Andretta et autres

OBJECTIVES: Drug-resistant epilepsy (DRE) remains a major clinical challenge, affecting approximately one-third of patients with epilepsy. Cenobamate, a novel antiseizure medication (ASM) approved in Italy in 2022, has shown promise in clinical trials. However, real-world data on its use, especially economic evaluations, …

gb, it, us (code pays fourni par la source)

Frequency of anticholinergic drug use in patients treated with aripiprazole once-monthly: a 2-year cohort study using European healthcare databases

Frank Andersohn, Pedro Such, Michael Jan, Uwa Kalu et autres

Background: Extrapyramidal symptoms (EPS) in association with the long-acting, injectable, atypical antipsychotic aripiprazole once monthly (AOM) have been observed in clinical trials, but information on EPS requiring treatment with anticholinergic drugs in clinical practice is limited. Objectives: The objective of this European …

de, dk, us, it, gb, se (code pays fourni par la source)

Characteristics and Drug Utilization of Patients with Hereditary Angioedema in Italy, a Real-World Analysis

Elisa Giacomini, Melania Leogrande, Valentina Perrone, Margherita Andretta et autres

This real-world analysis investigated the characteristics and treatment patterns of patients with hereditary angioedema (HAE) in Italy using the administrative data of health units across Italy. Patients were identified via exemption code or HAE-specific treatments (thus, all known forms, type I, II …

it (code pays fourni par la source)

Comparison of Direct Oral Anticoagulant Use for the Treatment of Non-Valvular Atrial Fibrillation in Pivotal Clinical Trials vs. the Real-World Setting: A Population-Based Study from Southern Italy

Ylenia Ingrasciotta, Andrea Fontana, Anna Mancuso, Valentina Ientile et autres

Patients enrolled into pivotal randomized controlled trials (RCTs) may differ substantially from those treated in a real-world (RW) setting, which may result in a different benefit–risk profile. The aim of the study was to assess the external validity of pivotal RCT findings …

it (code pays fourni par la source)

Real World Use of Antidiabetic Drugs in the Years 2011–2017: A Population-Based Study from Southern Italy

Ylenia Ingrasciotta, Maria Paola Bertuccio, Salvatore Crisafulli, Valentina Ientile et autres

Diabetes mellitus is a metabolic disease characterized by chronic hyperglycemia. The availability of new antidiabetic drugs (ADs) has led to complex treatment patterns and to changes in the patterns of specific drug utilization. The aim of this population-based study was to describe …

it (code pays fourni par la source)

Direct healthcare costs of chronic kidney disease management in Italy: What cost‐savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis‐stimulating agents?

Ylenia Ingrasciotta, Janet Sultana, Dario Formica, Valentina Ientile et autres

PURPOSE: Erythropoiesis-stimulating agents (ESAs), are used for treating chronic kidney disease (CKD)-related anemia, contributing to CKD costs. The study was aimed at investigating direct healthcare costs of CKD patients treated with ESAs and the potential savings achievable by increasing the use of …

it, in (code pays fourni par la source)

In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study

Ylenia Ingrasciotta, Valeria Belleudi, Francesco Trotta, Antonio Addis et autres

it (code pays fourni par la source)

Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study

Valeria Belleudi, Francesco Trotta, Antonio Addis, Ylenia Ingrasciotta et autres

INTRODUCTION: Real-world data on the comparative effectiveness and safety of switching among different epoetins (including originators and biosimilars) are limited. In light of current debate about interchangeability, prescribers, some patient groups and decision makers are calling for additional post-marketing evidence on the …

it (code pays fourni par la source)

Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study

Salvatore Crisafulli, Janet Sultana, Ylenia Ingrasciotta, Antonio Addis et autres

INTRODUCTION: Orphan drugs are medicines intended to treat, prevent, or diagnose a rare and serious condition. The collection of pre-marketing safety and efficacy data for orphan drugs is very challenging for several reasons related to the rarity of the diseases. This highlights …

it (code pays fourni par la source)

Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009–2014

Ilaria Marcianò, Ylenia Ingrasciotta, Francesco Giorgianni, Valentina Ientile et autres

Purpose Somatropin (rGH) is approved in children and adults for several conditions involving growth disturbances and the corresponding biosimilar is available in Italy since 2006. No population-based data are available on the pattern of rGH use in Italian clinical practice. This study …

it, nl (code pays fourni par la source)

Non-persistence risk and health care resource utilization of Italian patients with non-valvular atrial fibrillation

Nazarena Cataldo, Valeria Pegoraro, Claudio Ripellino, Valentino Bertasi et autres

The aim of this study is to compare discontinuation risk and health care resource utilization between vitamin K antagonists (VKAs) and non-vitamin K antagonist oral anticoagulants (NOACs) in newly treated patients with non-valvular atrial fibrillation (NVAF). Based on administrative databases of five …

gb, it, ar (code pays fourni par la source)